{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:07:10Z","timestamp":1793387230573,"version":"4.5.0"},"reference-count":67,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Hepatitis B virus (HBV) is a major global health issue, with an estimated 254 million people living with chronic HBV infection worldwide as of 2022. Chronic HBV infection is the leading cause of cirrhosis and liver cancer. Current treatment with nucleos(t)ide analogs is effective in the suppression of viral activity but generally requires lifelong treatment. They fail to eradicate the HBV viral reservoir, called covalently closed circular DNA (cccDNA), which replicates in the nucleus of liver cells. The cccDNA serves as the sole template for viral replication, as it generates the pregenomic RNA (pgRNA) necessary for producing new viral genomes. This stable form of viral DNA can reactivate the virus when treatment is stopped. HBV cccDNA is therefore one of the main challenges in curing chronic HBV infections. By targeting steps such as cccDNA formation, capsid assembly, or particle secretion, researchers continue to seek ways to interfere with HBV replication and to reduce its persistence, ultimately to eradicate HBV as a global health problem. This review provides an overview of what is currently known about cccDNA formation and biogenesis and the ongoing efforts to target and eradicate it to cure chronic HBV infections.<\/jats:p>","DOI":"10.3390\/biom15010062","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T09:17:02Z","timestamp":1736155022000},"page":"62","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["HBV cccDNA: The Molecular Reservoir of Hepatitis B Persistence and Challenges to Achieve Viral Eradication"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8607-1616","authenticated-orcid":false,"given":"Andr\u00e9","family":"Boonstra","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus Medical Center, Wytemaweg 80, 3015CN Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8585-5889","authenticated-orcid":false,"given":"Gulce","family":"Sari","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus Medical Center, Wytemaweg 80, 3015CN Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"ref_1","unstructured":"WHO (2024, April 09). Hepatitis B. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection--natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Trepo","year":"2014","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bpg.2017.05.003","article-title":"Hepatitis B virus infection and the immune response: The big questions","volume":"31","author":"Boeijen","year":"2017","journal-title":"Best Pract Res. Clin. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1128\/JVI.02741-06","article-title":"Hepatitis B virus subviral envelope particle morphogenesis and intracellular trafficking","volume":"81","author":"Patient","year":"2007","journal-title":"J. Virol."},{"key":"ref_6","unstructured":"European Association for the Study of the Liver (2017). Electronic Address, E. E. E. and European Association for the Study of The Liver, L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"Stein","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jmii.2022.06.002","article-title":"End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients","volume":"56","author":"Brakenhoff","year":"2023","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: Results from a randomised controlled trial (Toronto STOP study)","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/liv.15027","article-title":"The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia","volume":"42","author":"Toy","year":"2022","journal-title":"Liver Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0092-8674(80)90443-2","article-title":"Hepatitis B virus contains protein attached to the 5\u2019 terminus of its complete DNA strand","volume":"21","author":"Gerlich","year":"1980","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/hep.22881","article-title":"Hepatitis B: The virus and disease","volume":"49","author":"Liang","year":"2009","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"E5715","DOI":"10.1073\/pnas.1518090112","article-title":"Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation","volume":"112","author":"Tropberger","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hu, J., and Liu, K. (2017). Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application. Viruses, 9.","DOI":"10.3390\/v9030056"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100980","DOI":"10.1016\/j.jhepr.2023.100980","article-title":"Association of HBsAg levels with differential gene expression in NK, CD8 T, and memory B cells in treated patients with chronic HBV","volume":"6","author":"Beudeker","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jhep.2022.02.016","article-title":"Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection","volume":"77","author":"Montanari","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"U1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D Viruses Exploit Sodium Taurocholate Co-transporting Polypeptide for Species-Specific Entry into Hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterol"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1073\/pnas.1811064116","article-title":"Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization","volume":"116","author":"Iwamoto","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0021-9258(17)49936-4","article-title":"The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network","volume":"295","author":"Iwamoto","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Fukano, K., Tsukuda, S., Oshima, M., Suzuki, R., Aizaki, H., Ohki, M., Park, S.Y., Muramatsu, M., Wakita, T., and Sureau, C. (2019). Troglitazone Impedes the Oligomerization of Sodium Taurocholate Cotransporting Polypeptide and Entry of Hepatitis B Virus Into Hepatocytes. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.03257"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1128\/JVI.02303-05","article-title":"Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events","volume":"80","author":"Rabe","year":"2006","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9849","DOI":"10.1073\/pnas.1730940100","article-title":"Nuclear import of hepatitis B virus capsids and release of the viral genome","volume":"100","author":"Rabe","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s41467-021-21850-9","article-title":"Hepatitis B virus cccDNA is formed through distinct repair processes of each strand","volume":"12","author":"Wei","year":"2021","journal-title":"Nat. Com."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.1128\/JVI.01123-07","article-title":"Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: An intermediate of covalently closed circular DNA formation","volume":"81","author":"Guo","year":"2007","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wei, L., and Ploss, A. (2021). Mechanism of Hepatitis B Virus cccDNA Formation. Viruses, 13.","DOI":"10.3390\/v13081463"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.02007-17","article-title":"Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an In Vitro Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles","volume":"92","author":"Tu","year":"2018","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"104925","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antiviral. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/gutjnl-2023-330644","article-title":"Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B","volume":"73","author":"Testoni","year":"2024","journal-title":"Gut"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"104865","DOI":"10.1016\/j.antiviral.2020.104865","article-title":"A novel method to precisely quantify hepatitis B virus covalently closed circular (ccc)DNA formation and maintenance","volume":"181","author":"Tu","year":"2020","journal-title":"Antiviral. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100195","DOI":"10.1016\/j.jhepr.2020.100195","article-title":"Synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA","volume":"3","author":"Tu","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/gutjnl-2016-312162","article-title":"Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo","volume":"67","author":"Allweiss","year":"2018","journal-title":"Gut"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100514","DOI":"10.1016\/j.jhepr.2022.100514","article-title":"Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells","volume":"4","author":"Tu","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gomez-Moreno, A., and Ploss, A. (2024). Mechanisms of Hepatitis B Virus cccDNA and Minichromosome Formation and HBV Gene Transcription. Viruses, 16.","DOI":"10.3390\/v16040609"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jmb.2016.11.010","article-title":"A Molecular Prospective for HIRA Complex Assembly and H3.3-Specific Histone Chaperone Function","volume":"429","author":"Ricketts","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/nar\/gkad1200","article-title":"G-quadruplexes control hepatitis B virus replication by promoting cccDNA transcription and phase separation in hepatocytes","volume":"52","author":"Giraud","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41421-020-00218-1","article-title":"3D landscape of Hepatitis B virus interactions with human chromatins","volume":"6","author":"Yang","year":"2020","journal-title":"Cell Discov."},{"key":"ref_40","first-page":"1","article-title":"Nucleoside\/nucleotide analog inhibitors of hepatitis B virus polymerase: Mechanism, of action and resistance","volume":"8","author":"Alvarez","year":"2014","journal-title":"COVIRO"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","article-title":"Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B","volume":"66","author":"Lai","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_42","first-page":"314","article-title":"Reduction in Intrahepatic cccDNA and Integration of HBV in Chronic Hepatitis B Patients with a Functional Cure","volume":"11","author":"Gan","year":"2023","journal-title":"JCTH"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1136\/gutjnl-2022-328380","article-title":"Quantification of the hepatitis B virus cccDNA: Evidence-based guidelines for monitoring the key obstacle of HBV cure","volume":"72","author":"Allweiss","year":"2023","journal-title":"Gut"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41575-022-00649-z","article-title":"A roadmap for serum biomarkers for hepatitis B virus: Current status and future outlook","volume":"19","author":"Kramvis","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100841","DOI":"10.1016\/j.jhepr.2023.100841","article-title":"Evaluation of the HBV liver reservoir with fine needle aspirates","volume":"5","author":"Testoni","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Mu, D., Yuan, F.C., Chen, Y., Jiang, X.Y., Yan, L., Jiang, L.Y., Gong, J.P., Zhang, D.Z., Ren, H., and Liao, Y. (2017). Baseline value of intrahepatic HBV DNA over cccDNA predicts patient\u2019s response to interferon therapy. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-05242-y"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1002\/hep.31515","article-title":"Rapid turnover of HBV cccDNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients REPLY","volume":"73","author":"Liu","year":"2021","journal-title":"Hepatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0168-8278(99)80279-7","article-title":"Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells","volume":"31","author":"Rang","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1073\/pnas.252773599","article-title":"Transcriptional and posttranscriptional control of hepatitis B virus gene expression","volume":"100","author":"Uprichard","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jhep.2013.10.021","article-title":"Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration","volume":"60","author":"Allweiss","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Palumbo, G.A., Scisciani, C., Pediconi, N., Lupacchini, L., Alfaiate, D., Guerrieri, F., Calvo, L., Salerno, D., Di Cocco, S., and Levrero, M. (2015). Correction: IL6 Inhibits HBV Transcription by Targeting the Epigenetic Control of the Nuclear cccDNA Minichromosome. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0145555"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/nar\/30.9.2068","article-title":"Functional characterization of the interferon regulatory element in the enhancer 1 region of the hepatitis B virus genome","volume":"30","author":"Alcantara","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1128\/jvi.64.4.1821-1824.1990","article-title":"Alpha-Interferon Suppresses Hepatitis-B Virus Enhancer Activity and Reduces Viral Gene-Transcription","volume":"64","author":"Turkaspa","year":"1990","journal-title":"J. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2023.01.017","article-title":"Eliminating cccDNA to cure hepatitis B virus infection","volume":"78","author":"Zoulim","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2020-322571","article-title":"Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5\/6 complex and silencing of the viral genome in vivo","volume":"71","author":"Allweiss","year":"2022","journal-title":"Gut"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature17170","article-title":"Hepatitis B virus X protein identifies the Smc5\/6 complex as a host restriction factor","volume":"531","author":"Decorsiere","year":"2016","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e28578","DOI":"10.1002\/jmv.28578","article-title":"Sphondin efficiently blocks HBsAg production and cccDNA transcription through promoting HBx degradation","volume":"95","author":"Ren","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jhep.2022.12.014","article-title":"Discovery of a first-in-class orally available HBV cccDNA inhibitor","volume":"78","author":"Wang","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-\u03b3 and Tumor Necrosis Factor-\u03b1 Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterol"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.gastro.2018.03.027","article-title":"Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3","volume":"155","author":"Koh","year":"2018","journal-title":"Gastroenterol"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e49568","DOI":"10.15252\/embr.201949568","article-title":"Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20","volume":"22","author":"Stadler","year":"2021","journal-title":"Embo Rep."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Li, Y., Xia, Y., Han, M., Chen, G., Zhang, D., Thasler, W.E., Protzer, U., and Ning, Q. (2017). IFN-alpha-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-13082-z"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/1\/62\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:22:52Z","timestamp":1759918972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/1\/62"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["biom15010062"],"URL":"https:\/\/doi.org\/10.3390\/biom15010062","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]}}}